Remove 2012 Remove Leads Remove Pharmacology
article thumbnail

Botanical drugs – what is the best way forward for regulatory and market approval?

European Pharmaceutical Review

2 It was first approved as Fulyzaq in December 2012 and in October 2016, Napo Pharmaceuticals launched the new brand, Mytesi. 14 Marketing authorisation In the UK, medicinal products placed on the market are required to have marketing authorisations in accordance with The Human Medicines Regulations 2012 (S.I. 2012/1916).

Marketing 103
article thumbnail

Biosimilar medicines: the intersection of access, affordability, and innovation

European Pharmaceutical Review

Over 100 biosimilar medicines are approved for nearly 30 reference medicines, testimony to the rigour of the scientific standards leading to the European authorisation process. These reconsiderations lead the way to liberating untapped potential from biological standards of care. She holds a MSc in Pharmacology. References 1.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

MHRA Chief Executive to step down

European Pharmaceutical Review

Leading the MHRA – a five year journey Professor Graham Cooke, interim chair of the MHRA board, remarked that Dame June’s “leadership of the MHRA over the last five years, particularly during the COVID-19 pandemic, has been exceptional.”

Safety 111
article thumbnail

The Role of Certified Pharmaceutical Representatives in the Shifting Sales Landscape

Pharmaceutical Representative Training

Technological advancements, shifting market dynamics, and updated regulations are leading to significant changes within the pharmaceutical industry. The DOJ’s investigation revealed that the company misled HCPs and patients about the risks associated with the opioid, leading to overprescription and abuse. link] Reuters.

Sales 52